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Delayed Neurobehavioral Development in Children
Born to Pregnant Women with Mild Hypothyroxinemia
During the First Month of Gestation:
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Marisa Graells,5,{ Antonio Gonza´lez-Torga,6 and Gabriella Morreale de Escobar7
Background:Maternal hypothyroxinemia, due to gestational iodine deficiency, causes neurological dysfunctions
in the progeny. Our aim was to determine the effects of delayed iodine supplementation (200 mg KI per day) to
mildly hypothyroxinemic pregnant women at the beginning of gestation (i.e., having circulating free thyroxine
[FT4] within the 0th–10th percentile interval and normal thyrotropin [TSH]) on the neurobehavioral develop-
ment of their children.
Methods: Using the Brunet–Le´zine scale, we evaluated the neurocognitive performance at 18 months of age in
three groups of children. Group 1 included children of women with FT4 above the 20th percentile at 4–6
gestational weeks and at full-term. Group 2 included children of mildly hypothyroxinemic women diagnosed
during the first 12–14 gestational weeks and with FT4 above the 20th percentile at full-term. Group 3 included
children born to mildly hypothyroxinemic women at full-term, without iodine supplementation during gesta-
tion. Women of all groups were iodine supplemented from the day of enrollment until the end of lactation.
Results: Before iodine supplementation, 33.0% of the women (114 out of 345) were hypothyroxinemic, with FT4
belownormal in 28 of them (8.1%).Nonewere found to be hypothyroxinemic at full-term after supplementation. The
mean (SD) developmental quotient of children was 101.8 9.7 in group 1 (n¼ 13) vs. 87.5 8.9 in group 3 (n¼ 19;
p< 0.001) and 92.2 5.4 in group 2 (n¼ 12; p< 0.05). The difference between groups 2 and 3 was not statistically
significant. Delayed neurobehavioral performance was observed in 36.8% and 25.0% of children in groups 3 and 2,
respectively, compared with no children in group 1. Differences ( p< 0.001) were found on gross and fine motor
coordination and socialization quotients. No statistically significant differences were found on language quotients.
Conclusions: A delay of 6–10 weeks in iodine supplementation of hypothyroxinemic mothers at the beginning of
gestation increases the risk of neurodevelopmental delay in the progeny. Public health programs should address the
growing problem of iodine deficiency among women of gestational age in developing and industrialized nations.
Introduction
Iodine deficiency is one of the most frequent causesworldwide of preventablemental retardation in children. A
wide spectrum of iodine deficiency disorders has been de-
scribed during gestation, ranging from abortion to congenital
anomalies, deafness, neurological cretinism, neurocognitive
delay, and mental retardation, as well as attention deficit
hyperactivity disorder, among others (1,2). In children, the
severity of the neurodevelopmental damage caused by iodine
deficiency during gestation depends on the developmental
period affected by this condition and on its severity.
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Iodine is an essential component of the thyroid hormones,
thyroxine (T4) and triiodothyronine (T3). Iodine intake is es-
pecially crucial during gestation and lactation, since during
these developmental periods the mother is the only source of
iodine for the fetus and the neonate. Most critical for brain
development is the fact that T3 (the active hormone interacting
with nuclear thyroid receptors) is produced by the fetus from
maternal T4 and this is the only source of T4 for the fetus
during the first trimester of pregnancy (3–7). During this
critical period fundamental processes occur in the develop-
ment of the fetal central nervous system. In particular, the
cerebral vesicles, from which the cerebral cortex develops,
become recognizable in the developing central nervous sys-
tem by embryonic day 35 and the neocortical development
begins by embryonic day 46 (8). The concentration of T3 nu-
clear receptors is low at the beginning of neocortical devel-
opment but it progressively increases 10-fold by the 16th
week of gestation (9), in parallel to neuroblast proliferation
and neuronal migration (8). This makes the human brain
especially vulnerable during development to deficiencies of
iodine and thyroid hormones, not only because of their action
through nuclear receptors (9,10), but also for their possible
nongenomic effects that might take place even earlier. For
instance, recent studies have shown that thyroid hormone can
link integrin aVb3 receptor, which may induce angiogenesis
by activation of the mitogen-activated protein kinase signal
transduction cascade (11).
Epidemiological studies have shown neurological alter-
ations in children born to mildly to moderately hypothyrox-
inemic mothers: at least 50% of the offspring of women with
free T4 (FT4) below the normal 10th percentile had delayed
neurobehavioral development (12–15). An important pro-
spective study disclosed that the children ofmothers suffering
mild to moderate iodine deficiency during the first trimester
had an intelligence quotient (IQ) that was 10–15 points below
the normal mean values and that 11 of 16 children of the
moderately iodine-deficient area (68.7%) presented attention
deficit hyperactivity disorder (16). In contrast, none of the
children from mothers who were not hypothyroxinemic
during the first trimester had this syndrome.
Experimental studies performed in rodents are consistent
with the results from epidemiological studies: the tangential
and radial migrations of cortical neurons in the pups of hy-
pothyroxinemic dams are abnormal resulting in ectopic neu-
rons in different cortical layers, especially in the subcortical
white matter and in the alveus of the hippocampus. These
ectopias were found even when the maternal hypothyrox-
inemia was mild and transient at the beginning of cortico-
genesis (17–20). Whether or not such a critical period also
exists in humans at the beginning of corticogenesis is
unknown.
We here explore if mild and transient hypothyroxinemia in
pregnant women during the first trimester of gestation in a
mildly iodine-deficient region, when the bulk of fetal neo-
cortical proliferation has already occurred, may affect the
neurobehavioral development of their children.
Subjects and Methods
Subjects
This study was performed in the area of Marina Baixa
(Alicante, Spain). Three groups of pregnant women were in-
cluded (Table 1) and neurocognitive evaluation of strictly
selected children (Table 2) was performed at 18months of age.
These women were enrolled during the first 2–3 months after
the beginning of this study. Women of groups 1 and 2 were
enrolled at their first pregnancy visit (by a midwife or gyne-
cologist); women of group 3 were enrolled at full-term. All
women were supplemented orally with iodine (200mg KI per
day) from the day of enrollment to the end of lactation. The
Table 1. Number of Mothers with Different Serum Concentrations of Free Thyroxine and Thyrotropin
at Different Gestational Weeks
Group 1 KI from
4–6 GW (n¼ 92)
Group 2 KI from
12–14 GW (n¼ 102)
Group 3 KI after
delivery (n¼ 151)
At 4–6 GW At terma At 12–14 GW At termb At term
No hypothyroxinemia 64 (69.6%) 45 (100.0%) 73 (71.6%) 28 (100.0%) 94 (62.3%)
FT4 (20th–100th); normal TSH 46 (50.0%) 43 (95.6%) 48 (47.1%) 21þ 3c (85.7%) 59 (39.1%)
FT4 (10th–20th); normal TSH 17 (18.5%) 2 (4.4%) 24 (23.5%) 4 (14.3%) 32 (21.2%)
FT4 (20th–100th); TSH >4.80 1 (1.1%) 1 (1.0%) 3 (2.0%)
Hypothyroxinemia 28 (30.4%) 29 (28.4%) 57 (37.7%)
FT4 (0th–10th); normal TSH 22 (23.9%) 21 (20.6%) 40 (26.5%)
FT4 (0th–10th); TSH <0.38 2 (1.3%)
FT4< 0.71; normal TSH 6 (6.5%) 7 (6.9%) 15 (9.9%)
FT4< 0.71; TSH >4.80 1 (1.0%)
The FT4 concentration limits for the 0th–10th percentile interval are 0.71 and 0.82 ng=dL; for the 10th–20th percentile interval, 0.83 and
0.91 ng=dL; and for the 20th–100th percentile interval, 0.92 and 1.85 ng=dL. The normal range for FT4 is 0.71–1.85 ng=dL and for TSH is 0.38–
4.80mIU=mL. The groups from which the neurocognitive evaluated children were derived are indicated in bold.
aOnly women with FT4 within the 20th–100th percentile interval at 4–6 GW and with normal TSH are included in this column, one woman
that had a spontaneous abortion being excluded.
bOnly hypothyroxinemic women at 12–14 GW with normal TSH are included in this column, one woman with TSH above the normal
range being excluded.
cIncluding three out of seven women with FT4 below the normal range at 12–14 GW; the children of these women were excluded from
neurocognitive evaluation.
GW, gestational week; FT4, free thyroxine; TSH, thyrotropin.
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procedures followed were in accordance with the ethical
standards of the European Union on human experimentation
and approved by the Ethics Committee of the University
Miguel Herna´ndez.
Group 1 (Table 1) consisted of 92 women who were en-
rolled at 4–6 gestational weeks. Theywere then supplemented
with iodine (200mg KI per day) until full-term and throughout
lactation, with the exception of one case with thyrotropin
(TSH) >4.8 mIU=mL, who was referred to an endocrinologist
and excluded from the group. Neurocognitively evaluated
children (13 of 45 children) were born to women with normal
TSH and FT4 above the 20th percentile at the beginning of
gestation and at full-term, and not affected by the exclusion
criteria (32 of 45 children; Table 3).
Group 2 (Table 1) consisted of 102 women enrolled at the
beginning of the second trimester (12–14 gestational weeks).
Theywere then supplementedwith iodine (200mg KI per day)
until full-term and throughout lactation, with the exception of
two cases with TSH >4.8 mIU=mL, who were referred to an
endocrinologist and excluded from the group. Neurocogni-
tive evaluated children (12 of 21 children) were born to mildly
hypothyroxinemic women with normal TSH and with FT4
within the 0th–10th percentile interval during the first tri-
mester, and FT4 above the 20th percentile at full-term, and not
affected by the exclusion criteria (9 of 21 children; Table 3).
Group 3 (Table 1) consisted of 151 women enrolled at full-
term (37–40 gestational weeks); they were then supplemented
with iodine (200 mg KI per day) throughout lactation, with the
exception of five cases with abnormal TSH (three womenwith
TSH >4.80 mIU=mL, and two with TSH <0.38 mIU=mL), who
were referred to an endocrinologist and excluded from the
group. We performed neurocognitive evaluations on selected
children (19 of 41 children; two children were twins) born to
mildly hypothyroxinemic women at full-term defined as
having normal TSH and FT4 within the 0th–10th percentile
interval, andwho did notmeet any of the exclusion criteria (22
of 41 children; Table 3) defined in the exclusion criteria given
further on and in Table 2.
Thyroid function in all newborns was checked by the
Neonatal Thyroid Screening Program, based on circulating
TSH. No cases of congenital hypothyroidism were disclosed.
No further measurements of thyroid functionwere performed
in the children, although they were carefully evaluated every
3 months, until the 18th month of age, by the pediatrician
involved in this project, focusing on detection of possible
signs of thyroid malfunction. None of the evaluated children
showed signs of hyper- or hypothyroidism and all children
whowere later evaluated for their neurobehavior were breast-
fed for at least the first 6 months of postnatal life (Table 2).
Inclusion criteria
We included (i) pregnant women above the 20th percentile
at 4–6 gestational weeks and at full-term; (ii) pregnant women
with mild hypothyroxinemia as defined by FT4 levels within
the 0th–10th percentile interval of the normal distribution and
with normal TSH values at the end of the first trimester, and
with FT4 above the 20th percentile at full-term; and (iii)
pregnant womenwithmild hypothyroxinemia at full-term, as
just defined in (ii).
Exclusion criteria
We established these criteria to obtain comparably homo-
geneous groups of children excluding as many adverse factors
as possible (other than maternal hypothyroxinemia; Table 1)
that might affect both pre- and post-natal neurobehavioral
development of the child. These criteria are indicated in Table 2
and concern the medical history during gestation, at delivery,
and during lactation, including nutritional habits of pregnant
women and their intake of drugs, the health of children until
neurocognitive evaluation, and the socio-economic environ-
ment of the family.
Table 2. Epidemiological and Socio-Cultural
Exclusion Criteria
Cause for exclusion
Group 1
(n¼ 43)a
Group 2
(n¼ 21)
Group 3
(n¼ 40)
Total excludedb 30 9 22
Delivery
Death at birth 1 0 1
Caesarean section 8 4 8
Neonatal characteristicsc 3 1 4
APGAR <6 (at 5min
after birth)
2 1 1
Severe malformation 1 0 0
Severe disease 2 1 2
Early postnatal death 1 1 2
Abstinence syndrome 2 0 1
Lactation and 1st year of life
Lactation <6 months 3 1 1
Tonic neck reflex
at 8th month
0 0 1
Hypoacusia 2 1 1
Severe malformation 1 1 0
Blindness 1 0 0
Severe disease 3 0 2
Death 0 0 1
Poor parental care 0 0 1
Maternal
Weight increased 10 2 3
Toxic habits (drugs): 8 8 14
Alcohole 5 5 9
Tobaccof 6 4 9
Others 6 3 7
Sociocultural factors
Rural 5 1 4
Single parent family 3 0 1
School education
(<14 y)g
1 1 3
Unemploymentg 0 0 1
Without known
professiong
6 2 5
aThe total number (n) of women per group who passed the
inclusion criteria shown in Table 1.
bIncluding the cases that did not return for evaluation of the
children (10 cases in group 1, two cases in group 2, and three cases in
group 3).
cChildren with weight outside the 2500–4000g range, height
outside the 47–53 cm range, and cephalic perimeter outside the 33–
37 cm range.
dWomen with weight increase during gestation outside the 6–
15 kg range.
eDrinking other than 0mL throughout.
fSmoking more than 10 cigarettes per week throughout.
gBoth parents.
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At delivery, eachmother was interviewed by the physician,
filling in a questionnaire containing some of the exclusion
criteria. Women that passed these criteria at delivery were
interviewed 6 months later, and again those that passed the
criteria were newly interviewed the day of neurobehavioral
evaluation of the child. All mothers involved in this study
(who passed inclusion and exclusion criteria) were fully in-
formed and they consented to allow their infants to take part
in this study.
Neurobehavioral evaluation
The Brunet–Le´zine scale, revised in 1997 (21), was used to
estimate the neurobehavioral development of children at 18
months of age. The test consists of four subscales to assess
gross and fine motor coordination, language skills, and so-
cialization. The child’s scores on these four subscales deter-
mined a theoretical developmental age. The developmental
quotient for gross and fine motor coordination, language
skills, and socialization were calculated as the ratio between
the theoretical developmental and the actual age of the child.
Quotients between 85 and 115 indicate that the developmental
age of the child falls within the normal range. Performance on
the Brunet–Le´zine scales was classified according to their
quotients as significantly delayed (quotient: 69), mildly de-
layed (quotient: 70–84), normal (quotient: 85–114), and ac-
celerated (quotient: 115). For children in groups 1 and 2, the
determination of a child’s performance during neurobeha-
vioral evaluations was carried out masked in the presence of
two specialists who did not have access to the medical history
of the mothers. This was considered necessary because they
were evaluated during the same period of time. For children
of group 3, tests were not masked because they were born 8–9
months earlier than children of groups 1 and 2.
Biochemical analyses
Iodine concentrations were determined in spot urine sam-
ples by the ammoniumpersulfatemethod (22). SerumFT4 and
TSH were measured at the Hospital Marina Baixa, with an
ADVIA Centaur XP immunoassay system (Siemens Medical
Solutions Diagnostics Ltd., Llamberis, UK) using chemilu-
miniscence immunoassay kits. These kits contained primary
monoclonal anti-TSH and polyclonal anti-T4 antibodies. The
sensitivity was 0.3 ng=dL for FT4 and 0.03 mIU=mL for TSH.
The inter- and intra-assay coefficients of variation were lower
than those recommended by the Spanish Scientific Society of
Clinical Chemistry and Molecular Biology.
Statistical analysis
We used the SYSTAT statistical package (SYSTAT, Inc.,
Evanston, IL). Group comparisons were analyzed with the
Kolmogorov–Smirnov test and ANOVA using the Kruskal–
Wallis test for nonparametric distributions; levels of signifi-
cance were two-tailed.
Results
Epidemiological data
The Hospital Marina Baixa has an average of 1300 births
per year, 22% of them by cesarean section. Healthy neonates
leave the hospital 48–72 hours after birth; 83% are breast-fed
on average for 3.1 months. The age of women at full-term
ranged from 16 to 44 years (mean 31.1 years) and their weight
gain ranged from 6 to 39 kg (mean 12.5 kg). We found that
88% of the women reported eating fish at least twice weekly,
76% drinking daily 0.5 L of milk and milk-derived products,
and onewas a strict vegetarian. Of the total families, 83%were
urban and 21% were single parent. Only 8% of the women
were aware of the importance of the iodine intake during
gestation and 22% used certified iodized salt.
Spot iodine screening
Iodine concentrations (mg=L) of spot urine samples re-
vealed that mean values increased in groups 2 (96.7 39.9;
range: 10–220) and 1 (120.5 41.7; range: 20–285) with respect
to group 3 (74.6 0.8; range: 10–285; p< 0.001). In group 3,
only 4.7% had a urinary iodine >150mg=L vs. 33.3% in group
2 and 33.4% in group 1. On average, 24.1% had a urinary
iodine <50 mg=L in all groups (Fig. 1A).
Hormone screening before iodine supplementation
In all groups, the percentage of hypothyroxinemic women
with normal TSH was very high (on average 33.0%; Fig. 1A
and Table 1). On average, 7.8% of them had FT4 below the
normal range. Iodine-sufficient women with FT4 levels above
the 20th percentile ranged from 50.0% in group 1 at 4–6 ges-
tational weeks to 39.1% in group 3 at full-term. Abnormal
TSHwas found in one woman of group 1, two of group 2, and
five of group 3 (Table 1).
Table 3. Total Number of Women Enrolled, Cases that Meet the Inclusion Criteria
and that Were Excluded, and Children Evaluated
Group 1 Group 2 Group 3
Total women enrolled at the beginning of the study (at 4–6 GW
for group 1, at 12–14 GW for group 2, and at full-term for group 3)
92 102 151
Total no. of women that meet the inclusion criteria
at the beginning of the study
46 21 40
Total no. of women that meet the inclusion criteria at full term 43 21 40
Total no. of women=children who meet the exclusion criteria 20 7 19
Total no. of women who passed all criteria of exclusion
but that did not return for evaluation of the children
10 2 3
Total children who were evaluated when they were 18 months old
using the Brunet–Le´zine test
13 12 19 (2 twins)
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Effects of iodine supplementation
All supplemented women had normal FT4 above the 10th
percentile and normal TSH (Fig. 1C and Table 1). In group 1,
4.4% had FT4 within the 10th–20th percentile interval,
whereas in 95.6% it was higher. These valueswere also high in
group 2 (14.3% and 85.7%, respectively) and clearly lower in
group 3 (21.2% and 39.1%, respectively). The mean FT4 values
(ng=dL) increased in mothers of neurobehavioral evaluated
children in group 1 and 2 to 1.03 0.10 and 1.02 0.11 re-
spectively, as compared to the values of mothers in group 3,
0.77 0.04 ( p< 0.001; Table 4).
Neurocognitive development
Due to the strict exclusion criteria (Table 2), 13 children in
group 1 (14.1%), 12 in group 2 (11.8%), and 19 children in
group 3 (11.9%; two children were twins) were included for
neurobehavioral evaluation. The mean developmental quo-
tient in group 1 (101.8 9.7) was significantly higher than in
groups 3 (87.5 8.9; p< 0.001) and 2 (92.2 15.4; p< 0.05)
(Fig. 2A). Differences between groups 2 and 3 were not sta-
tistically significant ( p¼ 0.49). Accelerated performance was
only found in groups 1 and 2. In group 1, 15.4% of children
showed accelerated performance vs. 8.3% in group 2. Normal
performance also increased in group 1 (84.6%) with respect to
groups 2 (66.7%) and 3 (63.2%; Fig. 2B). Childrenwith delayed
performance were only observed in groups 2 (25%) and 3
(36.8%). These differences were also found when comparing
quotients in each one of the four scales of the Brunet–Le´zine
test. Statistically significant differences ( p< 0.001)were found
in gross and fine motor coordination and socialization scales,
with group 1 children obtaining the highest quotients (Fig.
2C). Mean language quotients were not statistically different
between groups ( p¼ 0.45).
Discussion
Our results show that a delay in maternal iodine supple-
mentation at the beginning of gestation increases the risk
of neurocognitive developmental delay of their offspring.
Despite the relatively small number of children evaluated in
this study, the developmental differences in those with late
supplementation were clearly significant. Also of note is the
finding that one third (33.0%) of the total group of pregnant
women (n¼ 345) included in this study had hypothyrox-
inemia at full-term or earlier in gestation with normal TSH,
indicating the high prevalence of dietary iodine deficiency
among women of reproductive age in this coastal region of
Spain. Children of mothers who suffered mild hypothyrox-
inemia during the first 12–14 gestational weeks (group 2)
FIG. 1. (A) Frequencies of urinary iodine concentra-
tions grouped in three intervals: below 50mg=L, within 51–
150 mg=L, and above 150mg=L. The percentage of women
with urinary iodine above 150 mg=L is lower in group 3
compared to groups 1 and 2. Frequencies of free thyroxine
(FT4) in ng=dL are grouped in four different intervals: below
the normal range (<0.71 ng=dL); within the 0th–10th per-
centile interval (0.71–0.82 ng=dL); within the 10th–20th per-
centile interval (0.83–0.91 ng=dL); and above the 20th
percentile (0.92–1.85 ng=dL). (B) Serum FT4 frequencies at 4–
6 weeks (group 1) and at 12–14 weeks of gestation (group 2).
(C) FT4 frequencies found at term. Note that in group 3 the
hormone determination was only performed at term. No
cases in groups 1 and 2 below the normal range
(<0.71 ng=dL) or within the 0.71–0.82 ng=dL interval were
found at term. *p< 0.001; n.s., no statistically significant
differences.
Table 4. Free Thyroxine and Thyrotropin
(Mean SD), at Term, of Mothers
of Neurocognitive-Evaluated Children
FT4 (ng=dL) TSH (mIU=mL)
Group 1 1.03 0.10 (0.93–1.20) 2.10 0.39 (1.09–2.60)
Group 2 1.02 0.11 (0.92–1.35) 2.28 0.89 (1.02–3.39)
Group 3 0.77 0.04 (0.71–0.82) 2.13 1.01 (0.57–3.96)
The ranges of values are shown within brackets. Statistically
nonsignificant differences were found in FT4 and TSH between
groups 1 and 2.
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showed lower performances in gross and fine motor coordi-
nation and socialization than those born to iodine-sufficient
women with FT4 above the 20th percentile at 4–6 gestational
weeks and at full-term (group 1). Performance in these three
categories decreased further in children of group 3 women
who were not supplemented with iodine during gestation.
Iodine supplementation did not cause thyroid function al-
terations in pregnant women: none of groups 1 and 2 women
receiving iodine supplementation were found to be hy-
pothyroxinemic at full-term and none had abnormal FT4 or
TSH.
This study has some unavoidable limitations. The number
of mothers and children that passed all the inclusion and ex-
clusion criteria was very low. Owing the low number of de-
liveries in the Hospital Marina Baixa (on average 1300 births
per year), only 345 women could be enrolled when the study
was started and 46 women (13.3% of cases) passed the in-
clusion and exclusion criteria. The number of enrolled moth-
ers per group could have been increased by keeping pregnant
women without iodine supplementation but that would not
have been ethically acceptable. Likewise, the number of chil-
dren per group was low due to our strict exclusion criteria,
which were established in order to obtain groups of children
growing in comparable social environments. Another limiting
factor was the determination of the thyroid function in preg-
nant women and in their children. Concentrations of iodine in
spot urine samples are adequate for epidemiological assess-
ments of the iodine intake of populations, but not for that of an
individual, as it varies considerably within a day and from
day to day. Circulating thyroid hormone determinations are a
more accurate procedure to assess thyroid function, and were
performed in all women at enrollment and at full-term, as-
suming that thyroid function was maintained within the ob-
tained values during this period. Confirmation of this
assumption by increasing the number of blood samples ob-
tained between enrollment and full-term (a procedure not
covered by our Public Health protocols) might have de-
creased the number of participating women and, as a conse-
quence, that of the children returning for neurobehavioral
evaluation. Thyroid function of the children was evaluated at
birth by the Neonatal Thyroid Screening Program, based on
circulating TSH, no further measurements beingmade, for the
same reason just indicated for the mothers.
Epidemiological studies performed in the Netherlands
(12–14), United States (15), and Russia (23) have shown neu-
rological alterations in children from mildly to moderately
hypothyroxinemicmothers. Furthermore, a prospective study
from Italy reported a positive correlation between iodine de-
ficiency during the first half of gestation and the IQ score of
their children (16). In addition, 68.7% presented attention
deficit hyperactivity disorder. In these studies, no signs of
clinical or subclinical hypothyroidism were observed in the
hypothyroxinemic mothers and their children were euthyroid
at birth. In agreement with the above studies, we observed
that children from groups 2 and 3 showed a significant
delay in neurobehavioral development compared to those
of group 1.
Using iodized salt and eating seafood 2–3 days per week,
a woman’s daily iodine intake would be in the order of
100–150 mg per day, approximately half the amount recently
recommended during pregnancy and lactation (24, 25). Sup-
plementation with 200mg KI per day during pregnancy and
FIG. 2. (A) Mean Brunet–Le´zine developmental quotients
(black bars; SD in vertical lines) of children from groups 1, 2,
and 3. No statistically significant differences were found
between groups 2 and 3. Boxes on the left indicate the me-
dian and interquartile ranges of the data distribution. (B) The
percentage of children with accelerated and normal perfor-
mances increases in group 2 but remains below the group 1
values. (C) Statistically significant differences between
groups were found in gross (GQ) and fine (FQ) motor co-
ordination, and socialization (SQ) quotients. Differences be-
tween groups 1 and 2 were found in GQ and FQ scales. No
difference between groups in language quotient (LQ) was
found. *p< 0.05; **p< 0.001; n.s., no statistically significant
differences.
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lactation does not block the developing thyroid gland of the
fetus and neonate (3,4). In contrast, iodine supplementation
from conception will ensure adequate maternal FT4 during
all of gestation and lactation; especially up to midgesta-
tion, when the fetal brain is particularly vulnerable to iodine
deficiency (3).
Iodized salt consumption, promoted for years in areas that
are now classified as free of iodine deficiency may not be
sufficient for pregnant women. In Teheran and Ilan (Islamic
Republic of Iran, which was declared free of iodine deficiency
by theWorld Health Organization in 2002), as many as 28% of
pregnant women had urinary iodine concentrations below the
value (150mg=L) that corresponds to the minimum accepted
iodine intake of 250mg per day (26). Similar findings were
reported from several European countries. In Poland, where
iodization of household salt became obligatory in 1997, only
37% of the pregnant women had urinary iodine concentra-
tions above 150 mg=L (27). Both a study performed in Boston,
where 9% of pregnant women had urinary iodine concen-
trations below 50mg=L (28), and a report of the National
Health and Nutrition Examination Surveys (NHANES III)
(29) have pointed out that urinary iodine is well below the
values recommended by the World Health Organization and
the International Council for Control of Iodine Deficiency
Disorders (28–30). To prevent iodine deficiency, the American
Thyroid Association (31) promoted iodine supplementation
for pregnancy and lactation in the United States and Canada,
recommending supplements of 150 mg iodine per day, this
being the maximum permitted in nutritional supplements for
pregnancy dispensed over-the-counter. Our present data re-
veal that this recommendation cannot cover the iodine re-
quirements of all pregnant women in mildly to moderately
iodine-deficient countries such as Spain and the United States,
among others (31). In fact, after 200mg KI per day supple-
mentation from 12 to 14 gestational weeks until end of lac-
tation to women in group 2, and from 4 to 6 gestational weeks
to women in group 1, urinary iodine increased in women of
these groups but still remained below the minimal values
(150 mg=L) recommended by the World Health Organization
(3,4): urinary iodine was on average 103.7mg=L, with only
33.4% having more than 150 mg=L and 23.8% having less than
50 mg=L. It would be very interesting to establish an individ-
ual subject correlation between urinary iodine and offspring
neurocognitive performance. However, it was not possible
since urinary iodine was determined at full-term from spot
samples. As already indicated above, the values obtained in
spot urine samples are appropriate for epidemiological sur-
veys of populations, but are inadequate for assessment of the
iodine availability of individualmembers (32). In addition to a
delay in iodine supplementation, differences in the degree
and=or duration of iodine deficiency during gestation might
also play a role. The high proportion of hypothyroxinemic
women found in this study (33.0%) reveals that normal iodine
intake has not been achieved and still remains a primary
public health problem even in developed countries. Similar
percentages of hypothyroxinemic pregnant women, or even
greater (up to 50%), have been found in countries supposed to
be iodine sufficient such as the United Kingdom (33).
The present results indicate a delay in neurocognitive de-
velopment of 18-month-old children from mildly hypothyrox-
inemic women who received delayed iodine supplementation
and are at risk of suffering permanent neurological alter-
ations. Although some of them might overcome delayed
neurobehavioral development when growing in an enriched
environment, the risk exists of suffering permanent neuro-
logical alterations. In fact, altered migration in the cerebral
cortex was found in rats and mice that suffered mild and
transient hypothyroxinemia for only 3 days at the beginning
of corticogenesis (18,20). This period of time might corre-
spond in humans to about 6 weeks of gestation, roughly from
embryonic day 46 until the end of the first trimester. In ad-
dition, T4 treatment of the rodents soon after inducing
maternal hypothyroxinemia prevented the neurodevelop-
mental damage. When treatment was delayed, the alterations
persisted (19).
Prospective studies on autism disorders (34,35) have found
that children diagnosed at 8–18 years of age had a more re-
tarded social development when they where 18 months old
than nonautistic ones (35). We have found that five children in
group 3 had a delayed development quotient, with sociali-
zation quotients more than 15 points below the fine motor
quotients, suggesting that they are at risk for developing
disorders of the autism spectrum. The hypothesis that these
children are at risk for developing disorders of the autism
spectrum is not unlikely. In fact, a recent study points out that
anti-thyroid environmental substances and pollutants can
affect the thyroid function during pregnancy, increasing the
risk of autism in the population (36).
Differences found in gross and finemotor coordination and
socialization skills, which involve neocortical areas as well as
other subcortical structures as the amygdaloid complex,
might indicate that early maternal hypothyroxinemia might
have affected maturation and=or cortical connectivity, as oc-
curs in animal models (18–20). In humans, these alterations
might be also present in those neocortical areas, other than
Broca’s and Wernicke’s, involved in language such as audi-
tory, visual, somatosensory, and motor areas. However, no
differences on language performance were found between
groups, which may reflect a deficient discrimination capacity
of the test in language performance in 18-month-old children.
Thus, language and other complex behaviors whose neural
substrates need thyroid hormone postnatally for a normal
development should be tested later, when these cortical areas
are in a more advanced stage of development.
In conclusion, implementation of universal salt iodization
and provision of iodine supplements during pregnancy and
lactation are intended to ensure that children reach their full
potential development, avoiding the tragedy of a mental re-
tardation caused by a preventable micronutrient deficiency.
We have found that a delay of 6–10 weeks in iodine supple-
mentation of pregnant women at the beginning of gestation in
an area of mild iodine deficiency increases the risk of their
offspring suffering permanent alterations in gross and fine
motor coordination and social development. Therefore, we
strongly support for this region the recommendation of a
daily 200mg iodine supplement to all women considering
conception, during pregnancy, and throughout lactation (3,4),
without wasting critical weeks for confirmation that iodine
intake is inadequate. Just as folates are recommendedwithout
awaiting confirmation of a possible folate deficiency, iodine
supplementation likewise should not be delayed. Our data
reveal that iodine supplementation is urgent and independent
from possible future implementation of thyroid function
screening of every woman at the beginning of pregnancy.
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